Class III glove box ALPHA-TIGHT SGS4030

containmentfor radioisotope preparationlaboratory

for containment of the At-211 radiopharmaceutical synthesis module Left part of working area provided of a well for the containment of the dose calibrator. Dimensions (lxdxh): working area mm 1400x700x900, prechamber inner dim. mm 300x300x460, well for containment of the dose calibrator mm 200x200x450 , Support mm 1300x700x850 , overall dim. mm 2005x950x2100 , Total weight kg. 450 approx Electric power supply: 230VAC Frequency: 50-60Hz Plug to a 230VAC - 2P+T 16 A S17 Internal power socket 230 V - 4A At-211 radiopharmaceuticals – the next frontier in cancer treatment Targeted radionuclide therapy is a precision medicine that uses radioactive substances attached to targeting moieties to specifically attack cancer cells. By labeling drugs with radioactive isotopes, radiation can be precisely delivered to cancer cells, reducing side effects compared to traditional therapies. Recently, targeted radionuclide therapies have grown significantly. At-211, with its short half-life, favorable decay chain, and scalable production, has unique properties as a payload for these radiopharmaceuticals. The Atley C100 module can both purify At-211 from irradiated cyclotron targets and synthesize At-211-based radiopharmaceuticals in an automated process. As a platform technology, the Atley C100 can be used to develop and manufacture multiple different At-211 radiopharmaceuticals. With its recent CE marking and CB certification, the Atley C100 is now available to researchers and drug developers worldwide, offering new possibilities in the field of targeted cancer therapy